Eledoisin
Eledoisin[edit]
Chemical structure of Eledoisin
Eledoisin is a naturally occurring peptide hormone that belongs to the tachykinin family. It was first isolated from the salivary glands of the European green lizard (Lacerta viridis) in 1961 by von Euler and Gaddum. Eledoisin is known for its potent vasodilatory effects and its role in regulating various physiological processes in the body.
Structure[edit]
Eledoisin is a linear peptide consisting of 11 amino acids. Its primary structure is as follows: pGlu-Pro-Ser-Lys-Asp-Ala-Phe-Ile-Gly-Leu-Met-NH2. The peptide is characterized by the presence of a pyroglutamate residue at the N-terminus, which enhances its stability and bioactivity. The C-terminal amide group is also important for its biological function.
Function[edit]
Eledoisin acts as a potent vasodilator by binding to the neurokinin-1 (NK1) receptor, which is widely distributed in various tissues including blood vessels, the central nervous system, and the gastrointestinal tract. Activation of the NK1 receptor by eledoisin leads to the release of nitric oxide and other vasodilatory substances, resulting in relaxation of smooth muscle and increased blood flow.
In addition to its vasodilatory effects, eledoisin has been implicated in the regulation of pain transmission, inflammation, and gastrointestinal motility. It is also involved in the modulation of neurotransmitter release and neurogenic inflammation.
Clinical Applications[edit]
Due to its potent vasodilatory effects, eledoisin has been investigated for its potential therapeutic applications. It has been studied as a treatment for conditions such as hypertension, migraine, and erectile dysfunction. However, further research is needed to fully understand its clinical potential and to develop specific eledoisin-based therapies.
References[edit]
